Semaglutide (Wegovy, Ozempic, Rybelsus) is a glucagon-like peptide-1 (GLP1) receptor agonist, and works by increasing insulin release, decreasing glucagon release, delaying gastric empty and reducing appetite. It is approved by the US FDA as a medicine for chronic weight management. It was reported that after taking semaglutide, patients can loss approximately 15% of initial weight at 68 weeks, and it also cause cardiovascular risks factors decrease and physical function increase. But there is also side effects and use contraindictions of this medicine, so, people should ask doctor before using it.
-X303.png)